Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

Objective It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and comp...

Full description

Bibliographic Details
Main Authors: Nick Bansback, Jeffrey R. Curtis, Jie Huang, Zeling He, Michael Evans, Tracy Johansson, Kaleb Michaud, Gabriela Schmajuk, Katherine P. Liao
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11106

Internet

https://doi.org/10.1002/acr2.11106

Similar Items